Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A promising new cell therapy called OSCA cut knee pain in half and showed early signs of cartilage regeneration in a phase IIa trial. The treatment — a single injection combining stem cells and cartilage matrix — could become the first true disease-modifying therapy for knee osteoarthritis. Results were presented at ACR Convergence 2026.
For decades, knee osteoarthritis (OA) patients have been stuck choosing between symptom management and joint replacement surgery. A new cell-based therapy called OSCA may finally offer a third path — one that actually repairs the damage.
Presented at ACR Convergence 2026, a phase IIa trial of 113 patients found that a single intra-articular injection of OSCA — combining cord blood-derived mesenchymal stem cells (osiramestrocel) with a pig-derived cartilage acellular matrix — cut pain scores by roughly half over 6 months. MRI findings also showed early cartilage regeneration and resolution of bone marrow abnormalities, while the placebo group saw continued joint deterioration.
By the Numbers:
Why it matters: If confirmed in larger trials, OSCA could be the first therapy to modify the underlying disease course of knee OA — not just mask symptoms — potentially reshaping how millions of patients are treated and reducing the need for joint replacement surgery.
